Baculoviral co-expression of HA, NA and M1 proteins of highly pathogenic H5N1 influenza virus in insect cells

Jundishapur Journal of Microbiology

Volumn 6, Issue 9, 2013, Pages

  Behzadian, Farida ^a   Goodarzi, Zahra ^b   Fotouhi, Fatemeh ^c   Saberfar, Esmaeil ^b  

^a MALEK ASHTAR UNIVERSITY OF TECHNOLOGY   (Iran)

^b BAQIYATALLAH UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c PASTEUR INSTITUTE OF IRAN   (Iran)

Author keywords

Baculovirus; H5 N1 Influenza Virus; Insect Cell; Recombinant Bacmid

Indexed keywords

BACULOVIRUS VECTOR; HEMAGGLUTININ; MATRIX PROTEIN; SIALIDASE; VIRUS VACCINE;

ARTICLE; DNA TRANSPOSITION; ESCHERICHIA COLI; GENE CASSETTE; GENE EXPRESSION; GENETIC TRANSFECTION; HA GENE; HOMOLOGOUS RECOMBINATION; IMMUNOGENICITY; INFLUENZA VIRUS A H5N1; INSECT CELL; M1 GENE; MOLECULAR CLONING; NA GENE; NONHUMAN; PLASMID; POLYMERASE CHAIN REACTION; PROTEIN EXPRESSION; VACCINE PRODUCTION; VIRUS GENE; VIRUS LIKE AGENT; VIRUS RECOMBINANT; VIRUS VIRULENCE;

AVIAN INFLUENZA VIRUS; ESCHERICHIA COLI; HEXAPODA; ORTHOMYXOVIRIDAE;

EID: 84889690123     PISSN: 20083645     EISSN: 20084161     Source Type: Journal    
DOI: 10.5812/jjm.7665     Document Type: Article

References (28)

1. Munster VJ, Fouchier RA. Avian influenza virus: of virus and bird ecology. Vaccine. 2009; 27(45): 6340-4.
2. Alexander Dennis J. A review of avian influenza in different bird species. Vet microbiol 2000; 74(1): 3-13.
3. Knipe DM, Howley P. Fields Virology.: Wolters Kluwer Health; 2013.
4. Wen Z, Ye L, Gao Y, Pan L, Dong K, Bu Z, et al. Immunization by influenza virus-like particles protects aged mice against lethal influenza virus challenge. Antiviral Res. 2009; 84(3): 215-24.
5. Hitchman RB, Possee RD, Crombie AT, Chambers A, Ho K, Siaterli E, et al. Genetic modification of a baculovirus vector for increased expression in insect cells. Cell Biol Toxicol. 2010; 26(1): 57-68.
6. Ligon BL. Avian influenza virus H5N1: a review of its history and information regarding its potential to cause the next pandemic. Semin Pediatr Infect Dis. 2005; 16(4): 326-35.
7. Ellebedy AH, Webby RJ. Influenza vaccines. Vaccine. 2009; 27 Suppl 4: D65-8.
8. Steel J. New strategies for the development of H5N1 subtype influenza vaccines: progress and challenges. BioDrugs. 2011; 25(5): 285-98.
9. Lambert Linda C, Fauci Anthony S. Influenza vaccines for the future. New England J Med. 2010; 363(21): 2036-2044.
10. Berger I, Fitzgerald DJ, Richmond TJ. Baculovirus expression system for heterologous multiprotein complexes. Nat Biotechnol. 2004; 22(12): 1583-7.
11. Bright RA, Carter DM, Daniluk S, Toapanta FR, Ahmad A, Gavrilov V, et al. Influenza virus-like particles elicit broader immune responses than whole virion inactivated influenza virus or recombinant hemagglutinin. Vaccine. 2007; 25(19): 3871-8.
12. Kang SM, Pushko P, Bright RA, Smith G, Compans RW. Influenza virus-like particles as pandemic vaccines. Curr Top Microbiol Immunol. 2009; 333: 269-89.
13. Ludwig C, Wagner R. Virus-like particles-universal molecular toolboxes. Curr Opin Biotechnol. 2007; 18(6): 537-45.
14. Krammer F, Grabherr R. Alternative influenza vaccines made by insect cells. Trends Mol Med. 2010; 16(7): 313-20.
15. Ausubel FM, Brent R, Kingston RE, Moore DD, Seidman JG, Smith JA, et al. Short Protocols in Molecular Biology.: Wiley; 2002.
16. Sambrook J, Fritsch EF, Maniatis T. Molecular Cloning: A Laboratory Manual.: Cold Spring Harbor laboratory Press; 1989.
17. Aucoin MG, Mena JA, Kamen AA. Bioprocessing of baculovirus vectors: a review. Curr Gene Ther. 2010; 10(3): 174-86.
18. Trowitzsch S, Bieniossek C, Nie Y, Garzoni F, Berger I. New baculovirus expression tools for recombinant protein complex production. J Struct Biol. 2010; 172(1): 45-54.
19. Federico Maurizio. Virus-like particles show promise as candidates for new vaccine strategies. Future virology. 2010; 5(4): 371-374.
20. Latham T, Galarza JM. Formation of wild-type and chimeric influenza virus-like particles following simultaneous expression of only four structural proteins. J Virol. 2001; 75(13): 6154-65.
21. Galarza JM, Latham T, Cupo A. Virus-like particle (VLP) vaccine conferred complete protection against a lethal influenza virus challenge. Viral Immunol. 2005; 18(1): 244-51.
22. Bright RA, Carter DM, Crevar CJ, Toapanta FR, Steckbeck JD, Cole KS, et al. Cross-clade protective immune responses to influenza viruses with H5N1 HA and NA elicited by an influenza virus-like particle. PLoS One. 2008; 3(1).
23. Quan FS, Steinhauer D, Huang C, Ross TM, Compans RW, Kang SM. A bivalent influenza VLP vaccine confers complete inhibition of virus replication in lungs. Vaccine. 2008; 26(26): 3352-61.
24. Sokolenko S, George S, Wagner A, Tuladhar A, Andrich JM, Aucoin MG. Co-expression vs. co-infection using baculovirus expression vectors in insect cell culture: Benefits and drawbacks. Biotechnol Adv. 2012; 30(3): 766-81.
25. Quan FS, Huang C, Compans RW, Kang SM. Virus-like particle vaccine induces protective immunity against homologous and heterologous strains of influenza virus. J Virol. 2007; 81(7): 3514-24.
26. Kang SM, Yoo DG, Lipatov AS, Song JM, Davis CT, Quan FS, et al. Induction of long-term protective immune responses by influenza H5N1 virus-like particles. PLoS One. 2009; 4(3).
27. Pushko P, Tumpey TM, Bu F, Knell J, Robinson R, Smith G. Influenza virus-like particles comprised of the HA, NA, and M1 proteins of H9N2 influenza virus induce protective immune responses in BALB/c mice. Vaccine. 2005; 23(50): 5751-9.
28. Pushko P, Tumpey TM, Van Hoeven N, Belser JA, Robinson R, Nathan M, et al. Evaluation of influenza virus-like particles and Novasome adjuvant as candidate vaccine for avian influenza. Vaccine. 2007; 25(21): 4283-90.